Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck, Schering-Plough resolve Vytorin investigation

This article was originally published in The Tan Sheet

Executive Summary

Merck and Schering-Plough will pay $5.4 million to 35 states and the District of Columbia to resolve an investigation into the firms' delayed release of negative study results for the cholesterol-lowering drug Vytorin. The agreement, which is not an admission of liability, covers the states' and D.C.'s investigative costs. The ENHANCE trial found Vytorin was no more effective in reducing plaque in carotid arteries than simvastin (1"The Tan Sheet" Feb. 4, 2008)

You may also be interested in...



FDA on ENHANCE

The agency will review the recently completed study of the Merck/Schering-Plough combination cholesterol therapy Vytorin after it receives the final results, according to a Jan. 25 announcement. The study found "no statistically significant differences" between a group receiving the highest dose of Vytorin (10 mg ezetimibe plus 80 mg simvastatin) and a group receiving 80 mg simvastatin in either the primary endpoint or in key secondary imaging endpoints (1"The Tan Sheet" Jan. 21, 2008, p. 12). Investigators in the firms' ENHANCE trial determined the primary endpoint - mean change in the intima-media thickness - through ultrasound measurements of the carotid arteries. FDA said it is not clear why the lower levels of LDL cholesterol in patients who took Vytorin did not lead to lesser amounts of plaque, compared to patients treated with simvastatin alone...

Vaccine Hesitancy May Drive Distribution Priorities For Early COVID-19 Supply

ACIP defers vote on who should be inoculated first until it has data on a specific product, but vaccine acceptance among different groups could be weighed as factor in setting distribution priorities, committee members suggest.

China’s Cosmetic Animal-Testing Exemption ‘Not A Terribly Meaningful Solution’ – PCPC

The Personal Care Products Council’s Francine Lamoriello, EVP of global strategies, discusses shortcomings of a proposed animal-testing exemption for imported general cosmetics under a key implementing regulation drafted for China’s new cosmetics oversight framework.

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel